Sage Therapeutics, Inc.
https://www.sagerx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sage Therapeutics, Inc.
In Medicare Drug Price Negotiations, Industry Sees Drawbacks And Silver Linings
Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.
Industry Looks At IRA Drawbacks And Silver Linings
Industry leaders are concerned about the outlook for small molecule drugs in particular, but execs at the J.P. Morgan Healthcare Conference were also optimistic there could be chances to shape the implementation of certain policies.
The Best Of J.P. Morgan – Valuations, Deals And The IRA
Scrip reporters spoke with many biopharma industry execs and observers during the J.P. Morgan Healthcare Conference in San Francisco – here are some of the highlights from interviews and presentations.
J.P. Morgan Day Four: Talking With Execs About BD Plans
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice